Cynata Therapeutics Ltd has released a press release.
Quarterly Activity Report & Appendix 4C
Filed with ASX ·
6ix hasn’t read this filing yet.
Cynata Therapeutics Limited on 6ix
Earlier from Cynata Therapeutics
- First Kidney Transplant Trial Patient Treated
- Cynata secures commitments for $8.1m institutional placement
- Demonstrated Safety & Efficacy in DFU Clinical Trial
- Trading Halt
- Cynata Receives $1.88m R&D Tax Incentive Refund
Later from Cynata Therapeutics
- Publication comparing Cymerus MSCs to other MSCs
- March 2025 Quarterly Activity Report and Appendix 4C
- CYP-001s FDA Approval Pathway Not Impeded
- June 2025 Quarterly Activity Report and Appendix 4C
- At-the-Market Subscription Agreement
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics